We are live on ! Find out more
WVP

Worth Venture Partners Portfolio holdings

AUM $31.6M
1-Year Est. Return 28.5%
This Fund
S&P 500
This Quarter Est. Return
+3.95%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
AUM
$180M
AUM Growth
+$47.3M
Cap. Flow
-$45.9M
Cap. Flow %
-25.57%
Top 10 Hldgs %
70.76%
Holding
129
New
37
Increased
17
Reduced
26
Closed
31

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$4.98M
2
AMGN icon
Amgen
AMGN
+$2.4M
3
BKNG icon
Booking.com
BKNG
+$2.14M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$2.13M
5
NNDM
Nano Dimension
NNDM
+$1.39M

Sector Composition

Rank Sector Weight
1 Healthcare 8.5%
2 Technology 5.71%
3 Consumer Discretionary 1.17%
4 Industrials 1.07%
5 Energy 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENTXW
76
DELISTED
Entera Bio Ltd. Warrant
ENTXW
$13K 0.01%
+13,943
New +$12.6K
GCVRZ
77
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$13K 0.01%
28,979
+1,944
+7% +$907
WFT
78
DELISTED
Weatherford International plc
WFT
$12K 0.01%
17,000
CZR
79
PUT
DELISTED
Caesars Entertainment Corporation
CZR
$11K 0.01%
16,649
-57,151
-77% -$495K
ABBV icon
80
PUT
AbbVie
ABBV
$455B
$7K ﹤0.01%
+22,500
New +$1.84M
KBR icon
81
PUT
KBR
KBR
$4.36B
$4K ﹤0.01%
10,737
-33,363
-76% -$603K
HLF icon
82
PUT
Herbalife
HLF
$1.29B
$2K ﹤0.01%
+1,496
New +$85.9K
NVAX icon
83
CALL
Novavax
NVAX
$1.22B
$2K ﹤0.01%
+2,175
New +$68.7K
ICPT
84
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1K ﹤0.01%
700
HSTO
85
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
$1K ﹤0.01%
232
+32
+16% +$12.9K
AGX icon
86
Argan
AGX
$8.13B
-5,211
Closed -$197K
ATNM icon
87
Actinium Pharmaceuticals
ATNM
$26.3M
-1,969
Closed -$22K
AXSM icon
88
Axsome Therapeutics
AXSM
$12.1B
-34,448
Closed -$96K
CALX icon
89
Calix
CALX
$2.22B
-113,996
Closed -$1.11M
INSM icon
90
PUT
Insmed
INSM
$22B
-95,500
Closed -$206K
LITE icon
91
Lumentum
LITE
$53.9B
-17,950
Closed -$754K
LTRX icon
92
Lantronix
LTRX
$239M
-142,500
Closed -$414K
OSS icon
93
One Stop Systems
OSS
$297M
-120,000
Closed -$232K
PBYI icon
94
CALL
Puma Biotechnology
PBYI
$402M
-20,000
Closed -$5K
PBYI icon
95
Puma Biotechnology
PBYI
$402M
-27,820
Closed -$565K
QMCO icon
96
Quantum Corp
QMCO
$443M
-8,425
Closed -$336K
SMTC icon
97
Semtech
SMTC
$10.7B
-8,601
Closed -$394K
SPSB icon
98
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.4B
-77,000
Closed -$2.32M
SPY icon
99
State Street SPDR S&P 500 ETF Trust
SPY
$784B
-1
Closed
VCSH icon
100
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.8B
-13,000
Closed -$1.01M

Similar funds

Worth Venture Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Worth Venture Partners held 129 positions worth $180M, up 36% from $132M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Worth Venture Partners withdrew a net $45.9M in Q1 2019, closing 31 positions and reducing 26 holdings. Its most notable exit was State Street SPDR Portfolio Short Term Corporate Bond ETF, an estimated $2.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.5% of assets, up from 3.7% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Worth Venture Partners opened a new position in Biogen worth $3.73M.

  • Worth Venture Partners's largest Q1 2019 buy was Biogen: 15,800 shares worth $3.73M.
  • Worth Venture Partners added most to BioMarin Pharmaceuticals in Q1 2019, an estimated $2.13M increase.
  • Worth Venture Partners's biggest Q1 2019 reduction was Qualcomm, cutting an estimated $2.81M.
  • Worth Venture Partners fully exited State Street SPDR Portfolio Short Term Corporate Bond ETF in Q1 2019, selling an estimated $2.32M.
  • Worth Venture Partners's ten largest holdings make up 71% of its $180M portfolio in Q1 2019.
  • Worth Venture Partners opened 37 new positions and closed 31 in Q1 2019.
  • Worth Venture Partners's portfolio value rose 36% quarter-over-quarter to $180M.

Based on Worth Venture Partners's 13F filing for Q1 2019, filed 15 May 2019.